-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Benzinga·10/09/2026 18:21:02
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.